WO2014180304A1 - Utilisation de composé j1-001 en tant que médicament anticancéreux - Google Patents

Utilisation de composé j1-001 en tant que médicament anticancéreux Download PDF

Info

Publication number
WO2014180304A1
WO2014180304A1 PCT/CN2014/076888 CN2014076888W WO2014180304A1 WO 2014180304 A1 WO2014180304 A1 WO 2014180304A1 CN 2014076888 W CN2014076888 W CN 2014076888W WO 2014180304 A1 WO2014180304 A1 WO 2014180304A1
Authority
WO
WIPO (PCT)
Prior art keywords
cells
tumor
cancer
compound
cell
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/CN2014/076888
Other languages
English (en)
Chinese (zh)
Inventor
刘天罡
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
WUHAN J1 BIOTECH CO Ltd
Original Assignee
WUHAN J1 BIOTECH CO Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by WUHAN J1 BIOTECH CO Ltd filed Critical WUHAN J1 BIOTECH CO Ltd
Publication of WO2014180304A1 publication Critical patent/WO2014180304A1/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/351—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom not condensed with another ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia

Definitions

  • the present invention relates to the field of biomedicine, and in particular to the use of a J1-001 compound as an anticancer drug. Background technique
  • the present invention is directed to solving at least some of the above technical problems or at least providing a useful commercial choice.
  • the object of the present invention is to propose the use of a J1-001 compound for inhibiting proliferation of tumor cells and/or tumor stem cells, which can be used for the treatment of cancer, in the preparation of a medicament.
  • the invention is a
  • a pharmaceutically acceptable salt thereof (herein, a compound of the formula I and a pharmaceutically acceptable salt thereof are collectively referred to as a J1-001 compound) can be used alone for inhibiting malignant cells, drug-resistant malignant cells and/or Or proliferation of cancer stem cells.
  • the invention provides the use of a compound of formula I, or a pharmaceutically acceptable salt thereof, for the manufacture of a medicament for inhibiting proliferation of tumor cells and/or tumor stem cells,
  • cancer stem cells maintain the vitality of tumor cell population through self-renewal and immortalization; the movement and migration ability of cancer stem cells make tumor cell metastasis possible; tumor stem cells can be dormant for a long time and have various tolerances. Drug molecules are not sensitive to the external physical and chemical factors that kill tumor cells, so tumors often recur after a period of time after conventional tumor treatment methods eliminate most common tumor cells. Thus, there is a need to develop a drug that inhibits the proliferation of cancer stem cells. According to an embodiment of the present invention, the inventors have found that the compound of the formula I or a pharmaceutically acceptable salt thereof can be used alone to inhibit the proliferation of cancer stem cells.
  • the inventors have unexpectedly found that breast cancer cell MCF-7 stem cells are mixed and cultured in vitro with a J1-001 compound, especially a J1-001 sodium salt.
  • the MTT colorimetric method was used to calculate the inhibition rate of J1-001 sodium salt on tumor stem cell proliferation and IC 5Q (half inhibition rate).
  • the inventors found that J1-001 sodium salt inhibited breast cancer cell MCF-7 stem cells.
  • the J1-001 sodium salt has a good inhibitory effect on the tumor stem cells, especially the breast cancer cells MCF-7 stem cells.
  • the inventors have found that the compound of the formula I or a pharmaceutically acceptable salt thereof can be used alone for inhibiting the proliferation of malignant tumor cells and drug-resistant malignant cells.
  • the inventors have unexpectedly discovered that the J1-001 compound can effectively inhibit the proliferation of malignant tumor cells and drug-resistant malignant tumor cells by mixing J1-001 compound with malignant tumor cells and drug-resistant malignant tumor cells.
  • the compound of the formula I or a pharmaceutically acceptable salt thereof can be used for the treatment of malignant tumor cells and drug-resistant malignant tumor cells, thereby providing a novel drug for treating such diseases.
  • pharmaceutically acceptable salt means a salt form commonly used in the field of medicinal chemistry, that is, substantially non-toxic and capable of providing the desired pharmacokinetic properties, orally, absorbing, distributing, metabolizing or The salt form of excretion.
  • the "pharmaceutically acceptable salt” may be a common acid addition salt or a base addition salt such as a potassium salt or a sodium salt.
  • the invention may also have the following additional technical features:
  • the tumor cells are malignant tumor cells and drug resistant malignant tumor cells.
  • the malignant tumor cell is at least one selected from the group consisting of a breast cancer cell, a liver cancer cell, a lung cancer cell, a gastric cancer cell, and an ovarian cancer cell.
  • the inventors discovered that the proliferation of malignant tumor cells can be inhibited by studying the use of the J1-001 compound. Therefore, further studies have found that the proliferation of breast cancer cells, liver cancer cells, lung cancer cells, gastric cancer cells and ovarian cancer cells Has an inhibitory effect.
  • the inventors will be MCF-7 (human breast cancer cells), Bel-7402 (human liver cancer cells), HepG2 (human liver cancer cells), NCI-H460 (human lung cancer cells), SGC-7901 ( Human gastric cancer cells and HO-8910 (human ovarian cancer cells) were mixed and cultured in vitro with J1-001 compound, especially its sodium salt.
  • J1-001 compound has a good inhibitory effect on the above tumor cells.
  • the inventors have also surprisingly found by analyzing the results of the examples that the J1-001 compound has a significantly stronger inhibitory effect on the proliferation of ovarian cancer cells than paclitaxel, thereby further illustrating the use of the J1-001 compound for the treatment of malignant tumors under these conditions. The superiority.
  • the drug resistant malignant tumor cell is selected from the group consisting of Bel-7402 liver cancer resistant cells and
  • the inventors By investigating the use of the J1-001 compound, the inventors unexpectedly found that it can inhibit the proliferation of drug-resistant malignant cells. According to a specific embodiment of the present invention, the inventors will have Bel-7402/5-Fu (human liver cancer resistant cells) or MCF-7/TAX (breast cancer resistant cells) and J1-001 compounds, especially J1-001 sodium salts. Mix culture in vitro. The MTT colorimetric method was used to calculate the inhibition rate and IC 50 (half inhibition rate) of J1-001 sodium salt on tumor cell proliferation. The inventors found that J1-001 sodium salt is resistant to human liver cancer resistant cells and human breast cancer resistant cells. It has an inhibitory effect. Thus, it can be concluded that the J1-001 sodium salt has a good inhibitory effect on drug-resistant malignant cells under these conditions.
  • the cancer stem cell is a breast cancer stem cell selected from the group consisting of MCF-7 (CD24-CD44 + ).
  • MCF-7 CD24-CD44 +
  • the inventors unexpectedly found that it can inhibit the proliferation of cancer stem cells by studying the use of the J1-001 compound.
  • the inventors mixed MCF-7 (CD24-CD44+) breast cancer stem cells with a J1-001 compound, especially a J1-001 sodium salt, in vitro.
  • MTT colorimetric method to calculate the inhibition rate of J1-001 sodium salt on tumor cell proliferation and IC 5Q (half inhibition rate)
  • J1-001 sodium salt against MCF-7 (CD24-CD44 + ) breast cancer stem cells It has an inhibitory effect.
  • the J1-001 sodium salt has a good inhibitory effect on breast cancer stem cell cells under these conditions.
  • the present invention provides a compound of formula I or a pharmaceutically acceptable salt thereof for use in the preparation of a medicament
  • the pharmaceutically acceptable salt is a sodium or potassium salt.
  • the cancer is at least one selected from the group consisting of breast cancer, liver cancer, lung cancer, gastric cancer, and ovarian cancer.
  • Formula I or a pharmaceutically acceptable salt thereof has an effect of inhibiting the proliferation of malignant tumor cells and drug-resistant malignant cells and/or tumor stem cells, and further, the inventors It has been found that Formula I or a pharmaceutically acceptable salt thereof is used as an active ingredient in the treatment of an anticancer drug to prepare an anticancer drug, and it is found to have a remarkable anticancer effect.
  • Formula I or a pharmaceutically acceptable salt thereof can be used as an active ingredient for the treatment of cancer drugs.
  • the above-described resistance comprising Formula I or a pharmaceutically acceptable salt thereof Cancer drugs can be used to treat or prevent breast cancer, liver cancer, lung cancer, stomach cancer and ovarian cancer.
  • the invention thus provides a novel use of Formula I or a pharmaceutically acceptable salt thereof, thereby providing a new class of anticancer drugs for the treatment of cancer.
  • Formula I or a pharmaceutically acceptable salt thereof can be used as an active ingredient in an anticancer drug, and particularly has a significant inhibitory effect on the proliferation of drug-resistant tumor cells and/or tumor stem cells, and thus can Fundamentally achieve the purpose of preventing and treating cancer.
  • the invention provides a pharmaceutical composition
  • a pharmaceutical composition comprising: a compound of formula I or a pharmaceutically acceptable salt thereof (collectively referred to as J1 -001 compound) ) and pharmacy
  • the pharmaceutical composition can effectively inhibit the proliferation of tumor cells and/or tumor stem cells, as well as for treating cancer.
  • the compound of the formula I may be produced by chemical synthesis or biosynthesis, for example, by microbial fermentation.
  • the pharmaceutically acceptable salt is a sodium or potassium salt.
  • pharmaceutically acceptable excipient may include any of the common excipients that may be used pharmaceutically, such as, but not limited to, binders, fillers, film-coated polymers, plasticizers, and helpers. Flowing agents, disintegrating agents, lubricants, and the like.
  • the pharmaceutical composition may further comprise minor amounts of auxiliary substances, such as wetting or emulsifying agents, preservatives or buffers, which may enhance the shelf life or efficacy of the pharmaceutical composition.
  • auxiliary substances such as wetting or emulsifying agents, preservatives or buffers, which may enhance the shelf life or efficacy of the pharmaceutical composition.
  • the pharmaceutical composition may be administered in a gastrointestinal dosage form and a parenteral administration form.
  • the gastrointestinal administration dosage form is a preparation in which the pharmaceutical composition enters the stomach and intestine after oral administration, and functions locally or absorbs at the administration site.
  • the parenteral administration form is a preparation in which the pharmaceutical composition functions in a local action or is absorbed after administration at a site other than an oral administration route.
  • the J1-001 compound or a pharmaceutically acceptable salt thereof acts on malignant tumor cells, drug-resistant malignant tumor cells, and/or cancer stem cells in various forms, and enhances treatment of malignant tumor cells in various ways, The effect of drug resistant malignant cells and/or cancer stem cells.
  • the J1-001 compound is an acidic ester-soluble polyether antibiotic, which has an inhibitory effect on Gram-positive and negative bacteria; has strong anti-coccidial activity, and is currently used for prevention and treatment. Laying hens and broilers Coccidiosis; At the same time, the toxicity and triad test results show that the antibiotic is safe and has no side effects.
  • the manner of obtaining the J1 - 001 compound is not particularly limited.
  • the J1 - 001 compound may be produced by fermentation with a microorganism containing a gene cluster encoding the compound, or may be Produced by chemical synthesis or chemical semi-synthesis.
  • the J1 -001 compound has long been used as an antibiotic for the control of chicken coccidia.
  • the antibiotic toxicity and triad test results show that it is safe and has no side effects. Therefore, the J1 - 001 compound has operability and applicability in preparation for pharmaceutical use. From the above, the J1-001 compound has great market prospects for the preparation of a medicament for treating malignant tumors.
  • the inventors unexpectedly found that the J1 -001 compound inhibited the proliferation of drug-resistant tumor cells significantly better than paclitaxel.
  • existing anticancer drugs have a good effect on the treatment of cancer in a certain period of time, but because of the long cycle of treatment of cancer, long-term use of a certain anticancer drug is prone to drug resistance. Therefore, there is a need to develop more drugs for treating cancer, especially drugs which have a significant inhibitory effect on tumor cells which have developed resistance.
  • the inventors have surprisingly found that the J1-001 compound is effective in inhibiting a variety of human malignant cells, particularly drug-resistant tumor cells, and its effect is superior to various existing chemotherapeutic drugs. Thereby, the superiority of the J1-001 compound as a medicament for treating malignant tumors is further improved.
  • the inventors have surprisingly found that the J1-001 compound can inhibit the proliferation of tumor stem cells, and the effect thereof is superior to various existing chemotherapeutic drugs, for example: J1-001 compound for tumor stem cells
  • the inhibition of proliferation is significantly stronger than that of doxorubicin, that is, the J1-001 compound is superior in the treatment of malignant tumor drugs.
  • the means for administering the prepared drug is also not particularly limited, such as parenteral administration (for example, intradermal, intramuscular, intraperitoneal, intravenous, and subcutaneous), epidural administration, tumor Internal administration and mucosal administration (eg, intranasal and oral routes).
  • parenteral administration for example, intradermal, intramuscular, intraperitoneal, intravenous, and subcutaneous
  • epidural administration for example, epidural administration
  • tumor Internal administration and mucosal administration eg, intranasal and oral routes.
  • the medicament of the present invention can be administered intramuscularly, intravenously, intratumorally, orally, intranasally, pulmonaryly, or subcutaneously.
  • the J1-001 compound can be administered by any convenient route, for example by infusion or a single rapid intravenous injection, by absorption through an epithelial or mucosal skin lining (eg, oral mucosa, rectum, and intestinal mucosa, etc.), by antibody protein specific treatment. And, and can be administered in conjunction with other biologically active agents.
  • the administration of the J1-001 compound may be systemic or topical administration.
  • a therapeutic agent of the invention in a region in need of treatment; this may be accomplished by, for example, but not limited to, local infusion, injection, or by implantation, the implant being porous Or non-porous materials, including membranes and matrices, such as silicone rubber membranes, polymers, fibrous matrices (eg, Tissuel®), or collagen matrices.
  • the implant being porous Or non-porous materials, including membranes and matrices, such as silicone rubber membranes, polymers, fibrous matrices (eg, Tissuel®), or collagen matrices.
  • Figure 1 shows the results of detection of IC 5Q of various cell lines under the action of J1 -001 sodium salt
  • Figure 2 shows the results of the effect of J1 -001 sodium salt on tumors in mice
  • FIG. 3 shows the results of the effect of J1 -001 sodium salt on breast cancer cells in mice. Detailed description of the invention
  • Example 1 Inhibition of proliferation of HO-8910 cells by J1-001 sodium salt and paclitaxel
  • HO-8910 ovarian cancer cells
  • HO-8910 ovarian cancer cells
  • HO-8910 ovarian cancer cells
  • HO-8910 ovarian cancer cells
  • HO-8910 ovarian cancer cells
  • the cell suspension was seeded in a 96-well cell culture plate at 200 ⁇ L per well; the blank group was a group containing 200 ⁇ of cell-free medium per well.
  • the above-mentioned cells-inoculated 96-well cell culture plates were placed in a cell culture incubator overnight to allow the cells to adhere.
  • sample J1-001 sodium salt and the existing anticancer drug paclitaxel were respectively dissolved in DMSO, and were prepared as a storage solution of 100 mmol/L, and then diluted into a sample solution of different concentrations (final concentration of DMSO less than 0.1%) with the corresponding medium before use.
  • sample solution 0.05, 0.1, 0.2, 0.5, 1.0, 2.0, 4.0, 8.0 ⁇ /L
  • paclitaxel solution 0.05, 0.1, 0.2, 0.5, 1.0, 2.0, respectively
  • the control group was a group in which 200 ⁇ medium was added to the adherent cells; the blank group was a group in which no cells were added with 200 ⁇ medium.
  • the 96-well cell culture plate supplemented with different concentrations of the drug solution (0.05, 0.1, 0.2, 0.5, 1.0, 2.0, 4.0, 8.0 ⁇ m ⁇ ⁇ / L sample solution or paclitaxel solution) was cultured in a cell culture incubator for 48 hours. 20 ⁇ 0.5 mg/mL of thiazolyl blue (MTT) was added to each well of the above-mentioned 96-well cell culture plate taken out, and then cultured in a cell culture incubator.
  • MTT thiazolyl blue
  • 96-well cell culture plates co-incubated with MTT were centrifuged at 2000 rpm for 10 minutes in a high speed centrifuge. After centrifugation, the supernatant in a 96-well cell culture plate was removed, and then the formazan blue crystals formed at the bottom of the 96-well plate were dissolved by adding 200 ⁇ L of dimethyl sulfoxide (DMSO) to each well.
  • DMSO dimethyl sulfoxide
  • the 96-well cell culture plate with DMSO was shaken on a plate shaker for 5 minutes, and the OD value (reference wavelength was 490 nm) was measured at 570 nm using an enzyme-linked immunosorbent assay to calculate the inhibition rate and IC 5Q. (half the inhibition rate).
  • Inhibition rate% ( A-Ao ) I ( ⁇ - ⁇ ) ⁇ 100%
  • ⁇ represents the OD value of the control group
  • a Q represents the OD value of the sample group
  • the experimental method is the same as in Example 1, except that the selected cell lines are MCF-7 (human breast cancer cells), Bel-7402 (human liver cancer cells), HepG2 (human liver cancer cells), NCI-H460 (human lung cancer). Cells), SGC-7901 (human gastric cancer cells) and HO-8910 (human ovarian cancer cells).
  • the experimental method was the same as in Example 1, except that the selected cells were Bel-7402 (human liver cancer cells); Bel-7402/5-Fu (human liver cancer resistant cells).
  • the thawed frozen HepG2-branch was quickly thawed at 37 °C, the force B RPMI1640 medium was 10 mL, and the lOOOO min 1 was washed twice, and the RPMI1640 medium containing 10% fetal bovine serum was added, 37 ° C, 5 % C0 2 incubator
  • the medium culture change the cell culture medium between days, and pass the cells to 70%-80% fullness.
  • After 1 week of culture collect the cell suspension, centrifuge lOOOrmin- 1 for 5 min, and adjust the cells to 1 mL per mL with serum-free medium. Contains lx lO 7 , spare.
  • mice 3 days after HepG2 cells were inoculated subcutaneously in the axilla of each 0.2 mL (lmL each containing 2> ⁇ 107 HepG2 cells). After the tumor was grown to a certain size, the tumor-bearing nude mice were sacrificed. The tumor-bearing mouse tumors were taken out under aseptic conditions, inoculated, and passed through the body for 3 generations. The tumor tissues were cut into l-3mm 3 small pieces in sterile PBS, inoculated by plugging method, and 30 naked in 6 weeks old. The rat armpit was inoculated subcutaneously with 0.2 mL, and the inoculation was observed.
  • Nude mice with tumor mass uniformity when the tumor volume was as long as 100 mm 3 were randomly divided into two groups: model group and J1-001 group, with 6 rats in each group, and a blank group. For the 21-day course, the blank, model group was given the corresponding volume of dilution. It was administered once every 4 days for 5 times. The activity and death of the nude mice were observed at the time of administration, and the tumor size was measured. The long diameter a and the short diameter b (mm) of the tumor were measured with a vernier caliper, and the tumor was weighed after the animal died. The following are specific groupings and administrations:
  • Blank group intraperitoneal administration (i.p.) 0.2mL/10g dilution solution
  • Model group intraperitoneal administration (i.p.) 0.2mL/10g dilution solution
  • J1-001 group intraperitoneal administration (i.p.) 0.2mL/10g 0.05mg/mL dose is lmg/kg
  • the animals were sacrificed after blood was taken (the serum was separated after blood was taken), and the tumor masses of each group were peeled off and weighed, and photographed after being placed.
  • Tumor inhibition rate (%) (model group tumor volume - experimental group tumor volume y model group tumor volume ⁇ ⁇ %;
  • MCF-7 human breast cancer cells
  • MCF-7/TAX human breast cancer resistant cells
  • the MCF-7, MCF-7/TAX cell suspension was inoculated into a 96-well plate, 100 ⁇ per well, and cultured in a 37 ° C, 5 % CO 2 incubator. After 24 h, the corresponding test drug was added to each well and cultured in an incubator at 37 ° C, 5 % CO 2 . After 24 h, CCk-8 reagent ⁇ ⁇ culture solution was added to each well, and the absorbance was measured at 450 nm.
  • Inhibition rate [( ⁇ 2- ⁇ 3)-( ⁇ 1- ⁇ 3)]/( ⁇ 2- ⁇ 3) ⁇ 100%
  • J1-001 sodium salt of J1-001 has strong antitumor activity against MCF-7, MCF-7/TAX tumor strains, and its IC 5Q values are similar. Compared to paclitaxel, J1-001 sodium salt exhibited lower IC 5Q for both MCF-7 and MCF-7/TAX. For MCF-7 tumor cell lines, the IC 5Q value of J1-001 sodium salt is about 10 times different from that of paclitaxel; for MCF-7/TAX tumor cell line, the IC 5Q value is about 282 times different from that of paclitaxel, suggesting that J1-001 sodium Salt has a unique advantage in fighting breast cancer.
  • Example 6 Effect of J1-001 sodium salt on anti-breast cancer tumor cells in vivo
  • mice around 5 weeks old were inoculated subcutaneously with 0.2 mL of MCF-7 cells (2 x 10 7 MCF-7 cells per ml) after 3 days.
  • the tumor-bearing nude mice were sacrificed.
  • the tumor-bearing mouse tumors were taken out under aseptic conditions, inoculated, and passed through the body for 3 generations.
  • the tumor tissues were cut into l-3mm 3 small pieces in sterile PBS, inoculated by plugging method, and 70 naked at 6 weeks old. Rats were inoculated subcutaneously with 0.2 mL to observe the inoculation.
  • Nude mice with tumor mass uniformity when the tumor volume was as long as 100 mm 3 were randomly divided into 5 groups: tumor-bearing saline group, tumor-bearing paclitaxel group (10 mg/kg), and tumor-bearing Jl-001 sodium salt high dose.
  • the blank, model group was given the corresponding volume of dilution.
  • the drug was administered once every 3 days for 5 times, and the animals were treated with blood after 20 days.
  • Blank group intraperitoneal administration (ip) 0.2ml/10g dilution solution,
  • Model group intraperitoneal administration (i.p.) 0.2ml/10g dilution solution
  • Paclitaxel group intraperitoneal administration (i.p.) 0.2ml/10g 0.5mg/ml dose of 10mg/kg,
  • Jl-001 sodium salt high dose group intraperitoneal administration (i.p.) 0.2ml/10g 0.05mg/ml dose is lmg/kg,
  • Jl-001 sodium salt low dose group intraperitoneal administration (i.p.) 0.2ml/10g 0.025mg/ml The dose is 0.5mg/kg.
  • Jl-001 sodium salt high dose group 4 1 0.35 ⁇ 0.05
  • Jl-001 sodium salt low dose group 5 0.5 0.40 ⁇ 0.19
  • Example 7 J1-001 sodium salt inhibits the proliferation of breast cancer cells MCF-7 stem cells
  • the MCF-7 cells in logarithmic growth phase were digested with 0.25%-EDTA trypsin to prepare a cell suspension with a concentration of 1 ⁇ 10 6 cells/mL, centrifuged at 500 g for 10 min, and the culture medium was changed to suspension culture solution. Take 1 mL of MCF-7 cell suspension, connect to a 75 cm 2 flask, add 9 mL of fresh suspension medium, and incubate in an incubator. After the cells were proliferated for two days, the cell suspension was centrifuged at 500 g for 10 min, resuspended in fresh suspension culture medium, repeatedly beaten as a single cell suspension, and counted at a cell density of 1 ⁇ 10 6 cells/mL. Cultivate the bottle.
  • the cell surface molecular markers (CD24 + / CD44 + / ) were identified by flow cytometry to identify tumor stem cell subsets.
  • Al-Hajj et al. Refer to: Al-Hajj M, etc., for the induction of tumorigenic breast cancer cells
  • Prospective identification of tumorigenic breast cancer cells Proc Natl Acad Sci USA. 2003, 100(7): 3983-8., which is incorporated herein by reference, for the detection of CD24-CD44+ in cells by flow cytometry.
  • the content of cells MCF-7 cells were cultured in suspension culture for 7 weeks. The cell suspension was digested with trypsin-EDTA and mechanically blown into a single cell suspension.
  • the cell density was adjusted to 1 ⁇ 10 8 cells/mL, and the cells were divided into cells.
  • Control group CD24 single staining group (CD24), CD44 single staining group (CD44) and double staining group (TEST), according to the following table, add the corresponding antibody solution for labeling, set at 4 ° C for 20 min after avoiding light
  • the cells were washed twice with PBS, the cells were resuspended, and the cells of the CD24 OD44+ phenotype were sorted by an upflow cytometer.
  • the sorted MCF-7 cells (CD24-CD44+) 500 g were centrifuged for 10 min, and the fresh suspension medium was replaced to adjust the cell density to 5 ⁇ 10 4 /mL; the MCF-7 adherent cells in the logarithmic growth phase were taken. After cellopreservation with 0.25%-EDTA trypsin, a cell suspension having a concentration of 5 ⁇ 10 5 /mL was prepared, and the above two cell suspensions were separately inoculated into a 96-well cell culture plate at 200 ⁇ per well.
  • each well cell was divided into a blank group, a control group and a drug-administered group, wherein the blank group was a cell-free group plus a medium, the control group was a medium to which cells were added, and the drug-administered group was a cell.
  • Different concentrations of test drugs were added, and doxorubicin was selected as a control for listed anti-tumor drugs in the test, as shown in Table 5 below.
  • the 96-well cell culture plate was cultured in a cell culture incubator for 48 hours, and 20 ⁇ 0.5 mg/mL of thiazolyl blue (MTT) was added to each well, and the cells were further cultured in a cell culture incubator for 2 hours, and then 96-well cells were added.
  • the plates were centrifuged at 2000 rpm for 10 minutes in a high speed centrifuge. After centrifugation, the supernatant in the 96-well cell culture plate was removed, and then 200 ⁇ l of dimethyl sulfoxide (DMSO) was added to each well to dissolve the formazan blue crystal formed at the bottom of the 96-well plate, using an enzyme-linked immunosorbent assay.
  • the OD value was measured at a wavelength of 570 nm (reference wavelength was 490 nm), and the inhibition rate was calculated and IC 5Q (half the inhibition rate) was obtained.
  • the results are shown in Table 6.
  • Inhibition rate% ( A-A0 ) I ( A-A1 ) l 00%, Where: A represents the OD value of the control group; AO represents the OD value of the sample group; A1 represents the OD value of the blank group.
  • the use of the J1-001 compound of the present invention as an anticancer drug is specifically: the use of a compound of the formula I or a pharmaceutically acceptable salt thereof for the preparation of a medicament for inhibiting tumor cells and/or tumor stem cells
  • the proliferation that is, the compound of the formula I or a pharmaceutically acceptable salt thereof can be effectively used for the preparation of a medicament for inhibiting the proliferation of tumor cells and/or tumor stem cells.

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La présente invention concerne l'utilisation d'un composé J1-001 en tant que médicament anticancéreux, qui consiste à utiliser un composé représenté par la formule I ou des sels pharmaceutiquement acceptables de celui-ci dans la préparation d'un médicament qui permet d'inhiber la prolifération de cellules tumorales.
PCT/CN2014/076888 2013-05-07 2014-05-06 Utilisation de composé j1-001 en tant que médicament anticancéreux Ceased WO2014180304A1 (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
CN201310163640 2013-05-07
CN201310163640.X 2013-05-07
CN201310298008.6A CN104138369B (zh) 2013-05-07 2013-07-16 抗癌药物
CN201310298008.6 2013-07-16

Publications (1)

Publication Number Publication Date
WO2014180304A1 true WO2014180304A1 (fr) 2014-11-13

Family

ID=51847823

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CN2014/076888 Ceased WO2014180304A1 (fr) 2013-05-07 2014-05-06 Utilisation de composé j1-001 en tant que médicament anticancéreux

Country Status (2)

Country Link
CN (1) CN104138369B (fr)
WO (1) WO2014180304A1 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017107993A1 (fr) * 2015-12-24 2017-06-29 武汉臻智生物科技有限公司 Utilisation d'un composé de polyéther

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107880060A (zh) * 2016-09-29 2018-04-06 武汉臻智生物科技有限公司 聚醚类化合物用途
CN107951879A (zh) * 2016-10-14 2018-04-24 武汉臻智生物科技有限公司 聚醚类化合物在制备药物中的用途及筛选抗癌药物的方法
CN108379251A (zh) * 2017-02-03 2018-08-10 武汉臻智生物科技有限公司 糖基聚醚类化合物作为抗癌药物的新机制研究发现
CN117024447A (zh) * 2023-07-12 2023-11-10 武汉合生科技有限公司 聚醚化合物及其制备方法

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2011213612A (ja) * 2010-03-31 2011-10-27 Kyowa Hakko Kirin Co Ltd 癌幹細胞及び／または癌前駆細胞の減少剤

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102675134B (zh) * 2012-05-29 2014-01-15 东南大学 含氮取代基姜黄素类似物及其药物用途
CN102746360B (zh) * 2012-06-19 2014-07-02 广西民族大学 四种喜树碱-甾体缀合物的合成及其应用

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2011213612A (ja) * 2010-03-31 2011-10-27 Kyowa Hakko Kirin Co Ltd 癌幹細胞及び／または癌前駆細胞の減少剤

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017107993A1 (fr) * 2015-12-24 2017-06-29 武汉臻智生物科技有限公司 Utilisation d'un composé de polyéther

Also Published As

Publication number Publication date
CN104138369A (zh) 2014-11-12
CN104138369B (zh) 2016-11-02

Similar Documents

Publication Publication Date Title
CN101273989B (zh) 一类小檗胺衍生物及其盐的应用
TW201138764A (en) Anticancer combinations of artemisinin-based drugs and other chemotherapeutic agents
WO2014180304A1 (fr) Utilisation de composé j1-001 en tant que médicament anticancéreux
WO2021012886A1 (fr) Composition pharmaceutique combinée antinéoplasique et son application
US9795595B2 (en) Methods for treating cancer
WO2013075607A1 (fr) Nouvelle utilisation d'acide chlorogénique contre le cancer
JP2019517477A (ja) 薬物抵抗性癌のための薬物送達ナノ粒子および治療
CN111358952B (zh) 一种抗肿瘤药物组合物及其制剂和应用
WO2020177748A1 (fr) Dérivé quaternisé de taxane modifié, et composition pharmaceutique et utilisation associées
CN116785267A (zh) 和厚朴酚在治疗耐药实体瘤以及耐药实体瘤的脑转移瘤中的用途
CN111803482B (zh) 鹿茸单体在制备抑制乳腺肿瘤骨转移的药物中的应用及药物
CN114222580B (zh) 一种预防和/或治疗卵巢癌的多肽药物及其用途
WO2018058863A1 (fr) Utilisation de composés de polyéther
CN111803484B (zh) 奥替溴铵在制备抗肿瘤药物中的应用
CN111803495B (zh) 盐酸苄达明在制备抗肿瘤药物中的应用
CN110856718A (zh) 苯并异硒唑衍生物与铂类药物联合用于制备治疗肿瘤药物与术后肿瘤复发药物中的应用
CN114010642A (zh) 一种治疗kras突变型肠癌的药物组合物及其联合用药物
WO2011113300A1 (fr) Médicaments pour l'inhibition de la toxicité ou d'effets secondaires provoqués par des agents chimiothérapeutiques
CN107281177B (zh) 促进造血干细胞归巢和植入的方法
CN111588714A (zh) 一种用于治疗肺癌的药物组合物及其制备方法
EP4591868A1 (fr) Médicament pour la prévention et le traitement d'une tumeur et utilisation associée
CN101653608B (zh) 含有肝细胞生长因子受体抑制剂和组蛋白去乙酰化酶抑制剂的药物组合物及其应用
CN101856359A (zh) 一种抗急性髓系白血病的药物组合物
TWI679013B (zh) 2β,3α,5α-三羥基雄甾-6-酮用於炎症反應的治療
Huang Novel Immunochemotherapy for Cancer Treatment

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 14794219

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 14794219

Country of ref document: EP

Kind code of ref document: A1